ArticleScientific reports2026
Targeting Crimean-Congo hemorrhagic fever virus: computational and MD-driven discovery of Moringa oleifera peptides against the RdRp-embedded OTU protease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structure-Guided Discovery and Biochemical Validation of Novel Small-Molecule Inhibitors Predicted to Target the CCHFV OTU Protease Y89-W99 Pocket.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne pathogen causes hemorrhagic disease with high fatality rates, and no approved vaccines/antivirals currently exist. The viral L protein contains a unique ovarian tumor (OTU) protease domain that cleaves ubiquitin and ubiquitin-like modifiers from host proteins, thereby aiding immune evasion and viral replication. Targeting the OTU domain represents a promising strategy for therapeutic intervention. Peptides obtained from Moringa oleifera proteome that mimic the binding mode of the endogenous ubiquitin molecule. These peptides were computationally screened for their ability to bind the OTU protease domain, incorporating both conventional cysteine protease inhibitors and protein-protein interaction interface mimetics. This study revealed Pep31 with a strong balance of binding affinity, solubility, and structural stability, highlighting its potential as a novel OTU protease inhibitor. While our findings are computational, they provide a foundation for experimental validation and the future development of peptide-based antivirals targeting CCHFV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.